股价走势图 数据来源：聚源 -40% 0% 40% 80% 120% 160% 2024-08 2024-12 2025-04 绿城中国 恒生指数 相关研究报告 房地产/房地产开发 绿城中国（03900.HK） 投资拿地强度大幅提升，减值拖累业绩水平 2025 年 08 月 25 日 投资评级：买入（维持） | 日期 | 2025/8/22 | | --- | --- | | 当前股价(港元) | 10.700 | | 一年最高最低(港元) | 13.780/0.000 | | 总市值(亿港元) | 271.74 | | 流通市值(亿港元) | 271.74 | | 总股本(亿股) | 25.40 | | 流通港股(亿股) | 25.40 | | 近 3 个月换手率(%) | 29.19 | 《单月销售金额实现增长，拿地强度 保持高位—港股公司信息更新报告》 -2025.6.10 《减值影响净利表现，周转提速，坚 决布局核心城市—港股公司信息更新 报告》-2025.4.1 《减值影响业绩表现，拿地强度维持 高 位 — 港 股 公 司 信 息 更 新 报 告 》 -2025.2.11 | ——港股公司信息更新报 ...

Investment Rating - The investment rating for the company is maintained at "Outperform" [1] Core Insights - The company has established a profitability turning point with significant growth in shipments, achieving a year-on-year increase of 132.57% in the first half of 2025 [5] - The second quarter of 2025 saw a revenue of 7.57 billion yuan, representing a year-on-year increase of 59.83% and a quarter-on-quarter increase of 93.05% [4] - The company is expected to benefit from increased production capacity and rapid development in its lightweight power business, leading to improved profit margins [6][7] Financial Performance Summary - In the first half of 2025, the company reported revenue of 11.49 billion yuan, a year-on-year increase of 33.75%, with a net profit of 0.14 billion yuan, down 30.01% year-on-year [4] - The gross margin for the second quarter of 2025 was 20.63%, up 6.39 percentage points quarter-on-quarter [4] - The company forecasts net profits of 2.46 billion yuan, 5.94 billion yuan, and 7.95 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.00 yuan, 2.42 yuan, and 3.24 yuan [4] Shipment and Market Development - The company achieved a shipment volume of 1328 MWh in the first half of 2025, with overseas shipments accounting for approximately 60% of total shipments [5] - The lightweight power business, which constitutes about 30% of total shipments, is expected to grow significantly, targeting a market share of over 5% this year [7]

汽车/汽车服务 途虎-W（09690.HK） 2025 年 08 月 25 日 投资评级：买入（维持） | 日期 | 2025/8/22 | | --- | --- | | 当前股价(港元) | 20.740 | | 一年最高最低(港元) | 25.000/14.360 | | 总市值(亿港元) | 170.86 | | 流通市值(亿港元) | 170.86 | | 总股本(亿股) | 8.24 | | 流通港股(亿股) | 8.24 | | 近 3 个月换手率(%) | 14.26 | 股价走势图 数据来源：聚源 -32% -16% 0% 16% 32% 48% 2024-08 2024-12 2025-04 途虎-W 恒生指数 相关研究报告 《收入规模稳定增长，门店扩张坚持 下沉战略—港股公司信息更新报告》 -2025.3.23 《门店维持高速扩张，利润率稳步提 升 — 港 股 公 司 信 息 更 新 报 告 》 -2024.9.3 门店持续扩张，精细化运营赋能增长韧性 ——港股公司信息更新报告 | 殷晟路（分析师） | 陈诺（分析师） | | --- | --- | | yinshenglu@kysec ...

Group 1 - The report highlights the positive signals in the merger and acquisition (M&A) market since 2024, driven by policies such as the new "National Nine Articles" and "M&A Six Articles," which encourage industrial integration and cross-border mergers [3][12][19] - The report emphasizes the importance of the Beijing Stock Exchange (BSE) in seizing M&A opportunities, particularly focusing on resource integration within the same group, external mergers in new productivity industries, and "strong chain and supplementary chain" expansions [3][20] - As of August 24, 2025, a total of 32 significant investment and M&A events have been disclosed on the BSE, indicating a growing trend in corporate acquisitions [22][26] Group 2 - The acquisition of 51% of Guangdong Pusen by Zhuozhao Point Glue for RMB 96.9 million is presented as a benchmark case of synergistic M&A between equipment and consumables [4][26] - The transaction aims to provide a comprehensive, one-stop service for customers by integrating point glue equipment and consumables, enhancing customer experience and satisfaction [4][31] - Zhuozhao Point Glue reported a turnaround in its financial performance for the first half of 2025, achieving revenue of RMB 156 million, a year-on-year increase of 207.46%, and a net profit of RMB 26.78 million, compared to a loss in the same period of 2024 [5][33] Group 3 - Guangdong Pusen specializes in point glue consumables, with major clients including well-known companies such as Samsung and BYD, positioning it as a strong competitor against international brands [48][49] - The acquisition is expected to enhance Zhuozhao Point Glue's market influence by integrating market resources and expanding customer coverage, particularly in the non-fruit chain sectors like new energy lithium batteries and semiconductors [32][34] - The original shareholders of Guangdong Pusen have committed to achieving a minimum net profit of RMB 19 million for the years 2025, 2026, and 2027, ensuring performance accountability post-acquisition [55][56]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has accelerated growth in Q2, with a focus on high-end brand development and ongoing global transformation [4][5] - In H1 2025, the company achieved revenue of 2.5 billion yuan, a year-on-year increase of 9%, and a net profit attributable to the parent company of 123 million yuan, up 16.5% year-on-year [5] - The company maintains its profit forecast, expecting net profits of 260 million, 320 million, and 400 million yuan for 2025, 2026, and 2027 respectively, representing year-on-year growth of 139%, 21%, and 25.1% [5] Financial Performance - In H1 2025, the company's self-owned brand revenue reached 1.04 billion yuan, accounting for 41.55% of total revenue, with a gross margin of 76.83%, up 5.7 percentage points year-on-year [5] - The overall gross margin for H1 2025 was 64.6%, an increase of 3.1 percentage points year-on-year, and the net margin was 4.9%, up 0.2 percentage points year-on-year [5] - The company’s financial metrics indicate a P/E ratio of 30.5 for 2025, 25.2 for 2026, and 20.1 for 2027 [5][7] Brand Development - The company is focusing on high-end brand construction, with significant improvements in brand structure and performance [4][5] - The EDB subsidiary achieved revenue of 150 million yuan in H1 2025, with a net profit of 35 million yuan, maintaining a net margin of 22.7% [5] - The company has successfully launched new products in the Chinese market and is experiencing rapid growth in online sales channels [5][6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a stable profit growth with an accelerated layout in innovative drugs, maintaining a "Buy" rating. In H1 2025, the company achieved revenue of 7.898 billion yuan (down 4.08% year-on-year) and a net profit attributable to shareholders of 785 million yuan (up 1.10%) [5][6] - The company has a strong focus on respiratory diseases, with over 10 innovative drugs in the pipeline, and is making significant progress in clinical trials for various treatments [6] Financial Summary - In H1 2025, the company's gross margin was 62.21% (down 1.10 percentage points), and the net profit margin was 22.33% (up 1.73 percentage points) [5] - The company expects net profits attributable to shareholders to be 1.463 billion yuan, 1.568 billion yuan, and 1.715 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.80 yuan, 0.86 yuan, and 0.94 yuan per share [5][8] - The current stock price corresponds to a PE ratio of 16.1, 15.0, and 13.7 for the years 2025, 2026, and 2027 respectively [5] Research and Development - The company has made multiple breakthroughs in research and development, particularly in the respiratory field, with innovative drugs targeting COPD and influenza [6] - The company is advancing its clinical trials for various drugs, including a non-opioid pain relief medication, which aims to provide safer alternatives for pain management [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6][16] Core Views - The company achieved a significant increase in non-recurring net profit, with a growth of 90.84% year-on-year, indicating strong operational performance despite a decline in net profit [6] - The company is expected to maintain a robust growth trajectory in its innovative pipeline, with projected net profits of 5.33 billion, 7.35 billion, and 10.31 billion for 2025, 2026, and 2027 respectively [6][9] - The current price-to-earnings (P/E) ratios are projected to decrease from 123.6 in 2025 to 63.9 in 2027, suggesting potential for valuation improvement [6][9] Financial Performance Summary - In H1 2025, the company reported operating revenue of 2.001 billion (up 18.63% year-on-year) and a gross margin of 72.96% (up 1.01 percentage points) [6][9] - The company’s R&D investment reached 497 million in H1 2025, reflecting a year-on-year increase of 43.02% [7] - The projected operating revenues for the years 2025 to 2027 are 4.364 billion, 5.312 billion, and 6.863 billion respectively, with corresponding year-on-year growth rates of 17.3%, 21.7%, and 29.2% [9][12] Innovative Pipeline and Market Position - The company has successfully maintained a leading market share of 22.3% in the intravenous anesthesia market with its product环泊酚, which is currently used in over 2,500 hospitals [7] - The company has several innovative products in various stages of development, including a first-class new drug for diabetic peripheral neuropathic pain and a high-selectivity peripheral κ-opioid receptor agonist [7] - The company’s innovative transformation is expected to drive future growth and enhance its market valuation [7]

Investment Rating - The investment rating for WuXi Biologics (02269.HK) is "Buy" (maintained) [4][13] Core Views - The company achieved a robust revenue growth of 16.08% year-on-year in H1 2025, with total revenue reaching 9.953 billion yuan and a net profit of 2.339 billion yuan, reflecting a significant increase of 56.05% [4] - The company has raised its full-year revenue guidance for 2025 to a growth range of 14%-16%, supported by a backlog of unfulfilled orders amounting to approximately 20.34 billion USD [4] - The report highlights the strong growth momentum in preclinical services and anticipates future growth in CMO (Contract Manufacturing Organization) business [5] Financial Performance - In H1 2025, the company reported a gross margin of approximately 42.73%, an increase of about 3.6 percentage points year-on-year [4] - The adjusted net profit for H1 2025 was 2.840 billion yuan, representing a year-on-year growth of 11.60% [4] - The company’s earnings per share (EPS) for 2025-2027 are projected to be 1.1, 1.3, and 1.5 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 26.7, 23.9, and 19.5 times [4] Business Growth and Strategy - The preclinical business achieved revenue of 4.147 billion yuan in H1 2025, marking a year-on-year growth of approximately 35.2% [5] - The company has a total of 864 projects in various stages, with 429 in preclinical, 259 in Phase I, 85 in Phase II, 67 in Phase III, and 24 in commercialization [5] - WuXi Biologics is expanding its global capacity with five research service centers, eight drug development centers, and eight commercial production centers [6] Regional Performance - Revenue growth in North America was robust at 20.1%, while Europe and China saw growth rates of 5.7% and a decline of 8.5% respectively [6] - The company’s strategic expansion in North America is expected to continue driving revenue growth [6]

房地产/房地产服务 | 日期 | 2025/8/22 | | --- | --- | | 当前股价(港元) | 5.090 | | 一年最高最低(港元) | 5.630/3.040 | | 总市值(亿港元) | 160.32 | | 流通市值(亿港元) | 160.32 | | 总股本(亿股) | 31.50 | | 流通港股(亿股) | 31.50 | | 近 3 个月换手率(%) | 10.86 | 股价走势图 数据来源：聚源 -24% 0% 24% 48% 72% 96% 2024-08 2024-12 2025-04 2025-08 绿城服务 恒生指数 相关研究报告 《各业务毛利率均提升，在管面积双 位数增长—港股公司信息更新报告》 -2025.3.24 《盈利能力同比提升，在管面积稳健 增 长 — 港 股 公 司 信 息 更 新 报 告 》 -2024.8.26 ——港股公司信息更新报告 | 齐东（分析师） | 胡耀文（分析师） | 杜致远（联系人） | | --- | --- | --- | | qidong@kysec.cn | huyaowen@kysec.cn | duzhiyuan@kys ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a significant increase in net profit for H1 2025, with a year-on-year growth of 44.3%, driven by product upgrades and channel expansion [5][6] - The company focuses on the fashion gold category, understanding the preferences of younger consumers, which has led to sustained high growth in performance [5] - The earnings forecast has been raised, with expected net profits for 2025-2027 at 550 million, 700 million, and 880 million yuan respectively, translating to EPS of 0.62, 0.79, and 0.99 yuan [5][8] Financial Performance Summary - For H1 2025, the company achieved revenue of 4.102 billion yuan, a year-on-year increase of 19.5%, and a net profit of 331 million yuan [5][6] - In Q2 2025, revenue was 1.850 billion yuan, up 13.1%, with net profit also increasing by 44.3% [5] - The company plans to distribute a dividend of 0.10 yuan per share [5] Product and Channel Analysis - In H1 2025, revenue from fashion jewelry, traditional gold, and leather goods was 1.99 billion, 1.83 billion, and 120 million yuan respectively, with year-on-year growth rates of 20.3%, 24.0%, and a decline of 17.4% [6] - The company has expanded its store count, adding 31 new stores in the jewelry business, with a net increase of 68 franchise stores, bringing the total to 1,542 [7] - The company is enhancing its product offerings, particularly in the gold category, with innovations that resonate with traditional Chinese culture [7] Financial Projections - The company’s revenue is projected to grow from 5.9 billion yuan in 2023 to 11.741 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 20% [8][11] - The net profit is expected to increase significantly from 333 million yuan in 2023 to 880 million yuan in 2027, reflecting a strong growth trajectory [8][11] - The projected P/E ratios for 2025, 2026, and 2027 are 24.6, 19.3, and 15.3 respectively, indicating a favorable valuation trend [8][11]